HK Stock Market Move | MEDBOT-B (02252) rose nearly 4%. The export value of surgical Siasun Robot & Automation has significantly increased, and the company's overseas scale effects are starting to show.

MEDBOT-B (02252) rose nearly 4%, and as of the time of writing, it increased by 3.36% to HKD 22.74, with a trading volume of HKD 67.78 million. In terms of news, Zhongtai released a research report stating that by 2025, the proportion of new installations of micro-invasive Siasun Robot & Automation and Jingfeng Medical in overseas markets will far exceed that in the domestic market. Over the past three years, the export value of surgical Siasun Robot & Automation has also significantly increased, contributing major installation flexibility during this period. The firm believes that China's laparoscopic surgery Siasun Robot & Automation industry is in the early stage of the penetration curve, with domestic companies achieving parity in hardware performance and leading in remote surgeries, while current domestic public tender data has surpassed imports, coupled with overseas expansion opening a second growth curve, positioning leading companies on the path to commercialization. Zhongtai stated that in the first half of 2026, micro-invasive Siasun Robot & Automation will turn a profit, with gross margins improving by more than 15 percentage points compared to the same period last year, entering a harvest phase. By June 2026, the company will have cumulatively installed over 200 units globally, and the effects of overseas scaling are beginning to manifest. The firm believes that domestic companies possess a first-mover advantage, leveraging 5G communication infrastructure, with Tumai having completed over 1,000 remote clinical surgeries, accounting for about half of the total global remote surgeries, and Jingfeng exceeding 500 cases, both with a success rate of 100%.